Q1 2026 Bausch Health Companies Inc Earnings Call Transcript
Key Points
- Bausch Health Companies Inc (BHC) reported a 14% increase in revenue for the first quarter of 2026, driven by strong performances from Salix and Solta.
- Adjusted EBITDA for Bausch Health, excluding Bausch + Lomb, increased by 17% on a reported basis, showcasing effective operational execution.
- The company successfully reduced its net debt by over $100 million, demonstrating progress in optimizing its capital structure.
- Bausch Health's acquisition of DURECT is advancing the Larsucosterol Phase 3 program for alcohol-associated hepatitis, indicating a focus on R&D innovation.
- The integration of the Shibo distribution business in China has led to significant revenue growth for Solta, highlighting successful strategic acquisitions.
- The diversified segment experienced a 10% decrease in revenue, primarily due to lower volume in the neuroscience business.
- The Canadian market contracted by 7% due to a drop in volume in the branded generic portfolio, impacting overall international performance.
- The company faces potential challenges from new tariffs on pharma products expected to be effective in September 2026.
- There is uncertainty regarding the impact of the DC Circuit Court's decision on Xifaxan's exclusivity, which could affect future cash flow.
- The company is dealing with legacy litigation settlements, which resulted in a $160 million outflow in the first quarter.
Greetings, and welcome to the Bausch Health's first-quarter 2026 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. (Operator Instructions)
It's now my pleasure to turn the call over to Garen Sarafian, Vice President, Investor Relations. Garen, please go ahead.
Good afternoon, and welcome to Bausch Health's first-quarter 2026 earnings conference call. My name is Garen Sarafian, Vice President of Investor Relations. Participating in today's call are Thomas Appio, Chief Executive Officer; JJ Charhon, Chief Financial Officer; and Jonathan Sadeh, Chief Medical Officer and Head of Research and Development.
Before we begin, I would like to remind you that today's presentation contains forward-looking information. Please take a moment to review the forward-looking statements disclaimer at the beginning of the slides accompanying this presentation, as it contains important information. Actual results may differ materially
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
